Developer of biophysical markers intended to revolutionize diagnostics using cell mechanics and machine learning. The company's biomarkers are based on mechanical properties of individual cells, by using microfluidics to route and probe cells, which can measure multiple biomarkers at one time, enabling physicians to detect early symptoms of sepsis, improving patient outcomes, and reducing treatment costs.
Employees: 11-50
Total raised: $283M
Founded date: 2013
Investors 5
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | Pathway Bi... | pathwaybio... |
| - | Dolby Fami... | dolbyventu... |
| - | Breakout L... | breakoutla... |
| - | Breakout V... | breakout.v... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 15.10.2024 | Series D | $100M | - |
| 17.11.2023 | Series C | $84M | - |
| 12.05.2023 | - | $84M | - |
| 30.10.2019 | - | $15M | - |
Mentions in press and media 16
| Date | Title | Description |
| 15.10.2024 | Cytovale's $100 Million Boost: A Game Changer in Sepsis Detection | Cytovale, a rising star in medical diagnostics, has secured a hefty $100 million in Series D funding. This investment, led by Sands Capital, signals a significant leap forward in the fight against sepsis, a condition that claims countless l... |
| 15.10.2024 | Cytovale: Medical Diagnostics Company Secures $100 Million (Series D) | Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced it has raised $100 million in Series D funding led by Sands Capital. ... |
| 11.10.2024 | Cytovale Secures $100M to Expand Commercialization of FDA-Cleared Sepsis Test | What You Should Know: – Cytovale, a medical diagnostics company revolutionizing early disease detection secures $100M in Series D funding round led by Sands Capital with participation from new investor Canada Pension Plan Investment Board (... |
| 10.10.2024 | Cytovale Completes $100M in Series D Funding | Cytovale, a San Francisco, CA-based commercial-stage medical diagnostics company, raised $100M in Series D funding. The round was led by Sands Capital with participation from new investor Canada Pension Plan Investment Board (CPP Investment... |
| 17.11.2023 | Machine learning medical diagnostics company Cytovale scores $84M | Photo: Johner Images/Getty Images |
| 15.11.2023 | Cytovale Raises $84M in Series C Funding | Cytovale, a San Francisco, CA-based commercial-stage medical diagnostics company, raised $84M in Series C funding. The round was led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health ... |
| 15.11.2023 | Cytovale Snags $84M To Commercialize Early Sepsis Detection Test | Sepsis kills more than 11 million people worldwide each year and contributes to 20% of all global deaths. The disease is also a leading cause of death in U.S. hospitals, and a septic patient’s risk of death increases by 8% each hour they go... |
| 15.11.2023 | Cytovale Fuels Sepsis Diagnostic Innovation with $84M in Funding | What You Should Know: Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C fu... |
| 12.05.2023 | Cytovale Secures $84M for Transformative Sepsis Diagnostic Tool | What You Should Know: Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C fu... |
| 30.10.2019 | Cytovale Announces $15M in Financing | SAN FRANCISCO, CA, Medical technology company announced $15 million in financing. >> Click here for more funding data on Cytovale >> To export Cytovale funding data to PDF and Excel, click here Cytovale, Inc., a medical t... |
Show more